[go: up one dir, main page]

ECSP19033211A - ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS - Google Patents

ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS

Info

Publication number
ECSP19033211A
ECSP19033211A ECSENADI201933211A ECDI201933211A ECSP19033211A EC SP19033211 A ECSP19033211 A EC SP19033211A EC SENADI201933211 A ECSENADI201933211 A EC SENADI201933211A EC DI201933211 A ECDI201933211 A EC DI201933211A EC SP19033211 A ECSP19033211 A EC SP19033211A
Authority
EC
Ecuador
Prior art keywords
antibodies
present
provides
methods
nucleic acids
Prior art date
Application number
ECSENADI201933211A
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Nancy E Stagliano
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of ECSP19033211A publication Critical patent/ECSP19033211A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona anticuerpos que se enlazan de una forma específica con el componente de la vía del complemento C1s. La presente invención proporciona ácidos nucleicos que comprenden las secuencias de nucleótidos que codifican los anticuerpos anti–C1s; y las células huéspedes que comprenden los ácidos nucleicos. La presente invención proporciona composiciones que comprenden los anticuerpos anti–C1s. La presente invención proporciona los métodos de uso de los anticuerpos anti–C1s.
ECSENADI201933211A 2016-10-12 2019-05-10 ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS ECSP19033211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12

Publications (1)

Publication Number Publication Date
ECSP19033211A true ECSP19033211A (es) 2019-07-31

Family

ID=61906346

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201933211A ECSP19033211A (es) 2016-10-12 2019-05-10 ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS

Country Status (34)

Country Link
US (2) US20200048332A1 (es)
EP (2) EP4652926A2 (es)
JP (3) JP7069138B2 (es)
KR (3) KR102638884B1 (es)
CN (2) CN116554320A (es)
AR (1) AR110677A1 (es)
AU (3) AU2017341766A1 (es)
BR (1) BR112019007309A2 (es)
CA (1) CA3040253A1 (es)
CL (1) CL2019000975A1 (es)
CO (1) CO2019004741A2 (es)
CR (1) CR20190223A (es)
DK (1) DK3525583T3 (es)
DO (1) DOP2019000085A (es)
EA (1) EA201990884A1 (es)
EC (1) ECSP19033211A (es)
ES (1) ES3049257T3 (es)
FI (1) FI3525583T3 (es)
HR (1) HRP20251304T1 (es)
IL (2) IL308156A (es)
LT (1) LT3525583T (es)
MX (2) MX2019004259A (es)
MY (1) MY198182A (es)
PE (1) PE20191031A1 (es)
PH (1) PH12019500789A1 (es)
PL (1) PL3525583T3 (es)
PT (1) PT3525583T (es)
RS (1) RS67326B1 (es)
SG (1) SG11201903012RA (es)
SI (1) SI3525583T1 (es)
TN (1) TN2019000109A1 (es)
TW (3) TWI773695B (es)
WO (1) WO2018071676A1 (es)
ZA (1) ZA201902247B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
ES2938359T3 (es) 2015-04-06 2023-04-10 Bioverativ Usa Inc Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
FI3525583T3 (fi) * 2016-10-12 2025-10-31 Bioverativ Usa Inc Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
CN115702165A (zh) * 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途
WO2021214759A1 (en) * 2020-04-22 2021-10-28 Chemomab Ltd. Method of treatment using anti-ccl24 antibody
WO2021231211A1 (en) * 2020-05-11 2021-11-18 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
CA3187866A1 (en) * 2020-08-06 2022-02-10 Jaime Morales ARIAS Inflammatory cytokines and fatigue in subject with a complement mediated disease
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
WO2023287573A2 (en) * 2021-07-13 2023-01-19 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
AU2023286689A1 (en) 2022-06-24 2025-02-06 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
AU2024237478A1 (en) 2023-03-16 2025-10-30 Genzyme Corporation Treatment of dry age-related macular degeneration

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
CA1276103C (en) 1984-10-02 1990-11-13 Fumiaki Taguchi Substance-conjugated complement component c1q
JPS61271455A (ja) 1985-05-28 1986-12-01 Olympus Optical Co Ltd 免疫学的分析方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
ES2171465T3 (es) 1993-09-01 2002-09-16 Sanquin Bloedvoorziening Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
PL186073B1 (pl) 1993-10-25 2003-10-31 Canji Preparat farmaceutyczny, zwłaszcza do terapii genowej
CN1160469C (zh) 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
HUP0000421A2 (hu) 1996-10-17 2000-06-28 Oxford Biomedica (Uk) Limited Retrovirális vektorok
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
AU762050B2 (en) 1998-02-20 2003-06-19 Genentech, Inc. Inhibitors of complement activation
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
WO2000064327A2 (en) 1999-04-26 2000-11-02 Duke University Inhibition of complement action
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
WO2001053825A1 (en) 2000-01-19 2001-07-26 Biotransplant, Inc. Swine defective for transmission of porcine endogenous retrovirus and uses thereof
ES2299473T3 (es) 2000-01-31 2008-06-01 Pharming Intellectual Property B.V. Inhibidor de c1 humano producido en la leche de mamiferos transgenicos.
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
US7071299B2 (en) 2000-06-21 2006-07-04 Zymogenetics, Inc. Peptide and polypeptide inhibitors of complement C1s
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1416962A4 (en) 2001-07-26 2006-05-24 Alexion Pharma Inc METHOD FOR IMPROVING THE COGNITIVE FUNCTION
CA2467959C (en) 2001-11-09 2009-03-10 Robert M. Kotin Production of adeno-associated virus in insect cells
JP2005515782A (ja) 2002-01-11 2005-06-02 ジーティーシー バイオセラピューティックス インコーポレイテッド 再構築された胚へ核を移植した後の融合および活性化のための方法およびシステム
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
AU2003270330B2 (en) 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
AU2004241069B2 (en) 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US20080075712A1 (en) 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
HRP20130440T1 (en) * 2004-04-13 2013-06-30 F. Hoffmann - La Roche Ag Anti-p-selectin antibodies
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA2847677C (en) 2004-06-10 2018-05-01 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1819731A4 (en) 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
ATE450522T1 (de) 2005-03-16 2009-12-15 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
WO2006131874A2 (en) 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
WO2007004670A1 (ja) 2005-07-05 2007-01-11 Kaneka Corporation メタクリル系樹脂組成物
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
WO2007070375A2 (en) 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
AU2006327989B2 (en) 2005-12-21 2012-06-07 Pharming Intellectual Property Bv Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
KR101513308B1 (ko) 2006-03-08 2015-04-28 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
DK3023500T3 (da) 2006-06-21 2020-04-20 Uniqure Ip Bv Insektceller til fremstilling af AAV-vektorer
BRPI0715869A2 (pt) 2006-09-05 2013-07-30 Alexion Pharma Inc mÉtodos e composiÇÕes para o tratamento de neuropatias mediadas por anticorpos
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
JP5586961B2 (ja) 2006-12-19 2014-09-10 バーシテック、リミテッド 合成イオンチャネル
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
SI2176296T1 (sl) 2007-07-16 2012-05-31 Genentech Inc Protitelesa proti CD b in imunokonjugati in postopki za uporabo
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
US7788398B2 (en) * 2007-08-08 2010-08-31 Swarmcast, Inc. Media player plug-in installation techniques
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
EP2282770B1 (en) 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
AU2009279197B2 (en) 2008-08-05 2013-12-12 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
EP2894166A1 (en) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP3460480B1 (en) 2008-12-01 2022-11-02 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
EP3153524B1 (en) 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
KR101759895B1 (ko) 2009-10-16 2017-07-20 오메로스 코포레이션 Ｍａｓｐ－2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법
WO2011102342A1 (ja) 2010-02-16 2011-08-25 国立大学法人京都工芸繊維大学 抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
SG183541A1 (en) 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
EP3514232A1 (en) 2010-04-23 2019-07-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
PT2563813E (pt) 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
US9090674B2 (en) 2010-05-17 2015-07-28 The Board Of Regents Of The University Of Texas System Rapid isolation of monoclonal antibodies from animals
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
UY33578A (es) 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
SI2648752T1 (sl) 2010-12-06 2017-06-30 Seattle Genetics, Inc. Humanizirana protitelesa proti Liv-1 in njihova uporaba za zdravljenje raka
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
EP3287142B1 (en) 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
RS60541B1 (sr) 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
DK2793935T3 (en) 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
JP6538561B2 (ja) * 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
KR101638931B1 (ko) * 2013-01-31 2016-07-12 서울대학교산학협력단 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
EP2996722A4 (en) 2013-05-15 2017-01-11 Annexon, Inc. Methods of treatment for guillain-barre syndrome
DK3725803T3 (da) 2013-05-23 2022-03-07 Broteio Pharma B V Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf
EA037325B1 (ru) * 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
MX2017004975A (es) 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
ES2938359T3 (es) * 2015-04-06 2023-04-10 Bioverativ Usa Inc Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
US20180169240A1 (en) 2015-06-26 2018-06-21 Bioverativ Usa Inc. Methods of treating autoimmune and alloimmune disorders
FI3525583T3 (fi) 2016-10-12 2025-10-31 Bioverativ Usa Inc Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
JP7293122B2 (ja) 2017-03-14 2023-06-19 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体が媒介する疾患および障害を処置するための方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2019250403A1 (en) 2018-04-13 2020-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-complement component antibodies and methods of use
SG11202103907PA (en) 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
CA3187866A1 (en) 2020-08-06 2022-02-10 Jaime Morales ARIAS Inflammatory cytokines and fatigue in subject with a complement mediated disease
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
AU2023286689A1 (en) 2022-06-24 2025-02-06 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Also Published As

Publication number Publication date
US12391750B2 (en) 2025-08-19
DOP2019000085A (es) 2019-07-31
AU2022205174A1 (en) 2022-09-29
EP3525583B8 (en) 2025-09-10
US20200048332A1 (en) 2020-02-13
CO2019004741A2 (es) 2019-07-31
EP3525583A1 (en) 2019-08-21
JP2020502996A (ja) 2020-01-30
PL3525583T3 (pl) 2026-01-19
PT3525583T (pt) 2025-10-22
JP2022105114A (ja) 2022-07-12
EP3525583B1 (en) 2025-07-23
EA201990884A1 (ru) 2019-10-31
ZA201902247B (en) 2024-07-31
MY198182A (en) 2023-08-09
AU2025267421A1 (en) 2025-12-04
TN2019000109A1 (en) 2020-10-05
HRP20251304T1 (hr) 2025-12-05
MX2019004259A (es) 2019-09-27
AU2022205174B2 (en) 2025-08-14
KR20250171438A (ko) 2025-12-08
KR20190082783A (ko) 2019-07-10
AU2017341766A1 (en) 2019-05-23
NZ753111A (en) 2025-06-27
JP2024038319A (ja) 2024-03-19
JP7069138B2 (ja) 2022-05-17
KR20240025715A (ko) 2024-02-27
JP7420864B2 (ja) 2024-01-23
BR112019007309A2 (pt) 2019-07-02
SG11201903012RA (en) 2019-05-30
DK3525583T3 (da) 2025-10-27
IL265957B1 (en) 2023-12-01
IL265957A (en) 2019-05-30
AR110677A1 (es) 2019-04-24
CA3040253A1 (en) 2018-04-19
ES3049257T3 (en) 2025-12-15
PH12019500789A1 (en) 2019-07-29
US20240076363A1 (en) 2024-03-07
MX2024008202A (es) 2024-07-15
PE20191031A1 (es) 2019-08-05
RS67326B1 (sr) 2025-11-28
IL265957B2 (en) 2024-04-01
KR102638884B1 (ko) 2024-02-22
CL2019000975A1 (es) 2019-10-04
EP3525583A4 (en) 2020-06-10
FI3525583T3 (fi) 2025-10-31
CR20190223A (es) 2019-08-21
EP4652926A2 (en) 2025-11-26
CN110300520B (zh) 2022-10-04
CN110300520A (zh) 2019-10-01
SI3525583T1 (sl) 2025-12-31
KR102891406B1 (ko) 2025-11-27
TW202434298A (zh) 2024-09-01
TWI846007B (zh) 2024-06-21
TWI773695B (zh) 2022-08-11
TW201821437A (zh) 2018-06-16
CN116554320A (zh) 2023-08-08
TW202246327A (zh) 2022-12-01
WO2018071676A1 (en) 2018-04-19
IL308156A (en) 2023-12-01
LT3525583T (lt) 2025-11-10

Similar Documents

Publication Publication Date Title
ECSP19033211A (es) ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CO2017011238A2 (es) Anticuerpos anti-c1s humanizados
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
BR112017003582A2 (pt) anticorpos, composições e usos
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CO2017012562A2 (es) Vectores virales adenoasociados que codifican para la enzima iduronato-2-sulfatasa
MX395149B (es) Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
MX2017006695A (es) Variantes de subtilasa y polinucleotidos que las codifican.
MX2018005070A (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
EA202193002A2 (ru) Соединение, нацеленное на ил-23a и фно-альфа, и его применение
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
CL2017000152A1 (es) Derivados de isoindolinona
EA201690383A1 (ru) НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ
CL2017003311A1 (es) Proteínas de fijación multiespecífica.
MX2018004187A (es) Metodos y composiciones para prevenir o tratar cancer.
AR103281A1 (es) COMPOSICIONES, APARATOS Y MÉTODOS PARA DETERMINAR EL pH DE UNA SOLUCIÓN DE ANALITO